Sanofi Patient Finder Suitability Analysis

Ada Health Patient Finder Opportunity Assessment
Analysis Date: March 11, 2026 | Analyst: Ada Cockpit Research Team

Executive Summary

Key Findings:

Portfolio Overview

Drug Primary Indication(s) FY 2025 Revenue Fit Score Tier Addressable Undiagnosed (USA) Ada Revenue Opportunity (5% capture/year)
Nexviazyme Pompe disease (LOPD) €700-800M 10/10 1 8,000-10,000 $11.25M
Dupixent AD, asthma, COPD, CSU, CRSwNP, EoE, PN, BP, AFRS €15,700M 9/10 1 6,400,000 $704M
Fabrazyme Fabry disease €1,019M 9/10 1 10,000-12,000 $9.35M
Sarclisa Multiple myeloma (R/R, NDMM) €588M 6/10 2 2,250 $1.13M
ALTUVIIIO Hemophilia A €1,160M 3/10 NO <500 —
Beyfortus RSV prevention €1,800M 2/10 NO 0 —
Lantus/Toujeo Diabetes €3,095M 1/10 NO 0 —
Aubagio Multiple sclerosis €238M 1/10 NO 0 —
Total Ada Revenue (5% capture, Tier 1+2)
$725.7M/year
Total Sanofi Drug Revenue Unlocked
$7.26B/year
Total Addressable Patients (USA)
6.42M
Average Diagnostic Delay
5-10 years

Detailed Drug Analysis

Market Opportunity

Region Addressable Undiagnosed Net Revenue/Patient Ada Revenue Opportunity (5% capture)
USA 8,000-10,000 $250,000/year $11.25M/year
DACH 4,500-5,500 $420,000/year $10.5M/year
ROW 15,000-16,000 $190,000/year $14.7M/year

Clinical Profile

  • Diagnostic Delay: 5-10+ years from symptom onset to diagnosis
  • Underdiagnosis Rate: >90% (North American registries capture <5% of expected LOPD patients)
  • Symptoms: Progressive proximal muscle weakness, respiratory insufficiency, elevated CK
  • Common Misdiagnoses: Limb-girdle muscular dystrophy, polymyositis, "deconditioning"

Ada Surface Ability: 10/10

Perfect fit. Symptom triad (progressive weakness + respiratory issues + elevated CK) identifiable by symptom assessment. Decision support critical for rare disease where PCPs/neurologists unlikely to suspect without prompting. GAA enzyme test readily available (blood test). Digital engagement high (ages 20s-70s).

Company Motivation: 10/10

  • Massive underdiagnosis: <5% of expected LOPD patients diagnosed
  • Revenue opportunity: $2.25B addressable USA (10x current US revenue)
  • Competitive urgency: Gene therapy pipeline threatens ERT market
  • Rare disease strategy: Genzyme legacy; patient finding aligns with mission
Pitch Hook: "Over 20,000 Americans with late-onset Pompe disease remain undiagnosed for 5-10+ years while their muscles and lungs fail, with registries capturing less than 5% of expected patients—and at $250,000 annual revenue per patient, Ada Patient Finder can identify these patients through symptom assessment years earlier, unlocking a $2+ billion addressable US market for Nexviazyme."

Market Opportunity

Region Addressable Undiagnosed Net Revenue/Patient Ada Revenue Opportunity (5% capture)
USA 6,400,000 $22,000/year $704M/year
DACH 920,000 $13,700/year $63M/year
ROW 18,000,000 $10,000/year $900M/year

Approved Indications (9 total)

  1. Atopic dermatitis (moderate-to-severe, ages 6 months+)
  2. Asthma (moderate-to-severe eosinophilic, ages 6+)
  3. COPD (with type 2 inflammation, adults)
  4. Chronic spontaneous urticaria (CSU, ages 12+)
  5. Chronic rhinosinusitis with nasal polyps (CRSwNP, ages 12+)
  6. Eosinophilic esophagitis (EoE, ages 1+)
  7. Prurigo nodularis (PN, adults)
  8. Bullous pemphigoid (BP, adults)
  9. Allergic fungal rhinosinusitis (AFRS, ages 6+)

Top 3 Addressable Indications

Indication Addressable USA Underdiagnosis Rate Diagnostic Delay
COPD (eosinophilic) 3.9M 70-90% 5 years avg
Atopic Dermatitis 1.7M 50%+ 1-3 years
Eosinophilic Asthma 460K 20-30% 1-2 years

Ada Surface Ability: 9/10

COPD: Dyspnea + chronic cough + smoking history + age 40+ → spirometry referral. Poor inhaler control + exacerbations → blood eosinophils + biologic.

AD: Chronic itch + flexural rash + sleep disruption + topical failure → dermatology for biologic.

Asthma: Nighttime symptoms + exacerbations + poor control → eosinophil testing + biologic.

Deduction (9/10 not 10/10): Requires specialist gatekeeping (spirometry for COPD, dermatologist for AD). Prior authorization delays access.

Company Motivation: 10/10

  • Revenue dependency: 36% of total Sanofi revenue (€15.7B of €43.6B)
  • Patent cliff 2031: 5 years to maximize patient capture
  • Massive TAM: 6.4M addressable USA (vs. 1M+ global patients treated)
  • COPD "substantial runway": CEO language signals strategic priority
Pitch Hook: "Over 6 million Americans with COPD, atopic dermatitis, and eosinophilic asthma who could benefit from Dupixent remain undiagnosed or misdiagnosed—waiting an average of 5 years for COPD, 1-3 years for AD specialist care—and at $22,000 net revenue per patient annually, Ada Patient Finder's symptom assessment can identify these patients years earlier, unlocking a $140 billion addressable US market while Dupixent generates 36% of Sanofi's total revenue."

Market Opportunity

Region Addressable Undiagnosed Net Revenue/Patient Ada Revenue Opportunity (5% capture)
USA 10,000-12,000 $170,000/year $9.35M/year
DACH 4,400 $111,000/year $2.44M/year
ROW 13,750 $100,000/year $6.88M/year

Clinical Profile

  • Diagnostic Delay: 10-15 years average (classic 5-10 years, later-onset 10-20+ years)
  • Underdiagnosis Rate: 82% USA (40,800 undiagnosed vs. 9,200 diagnosed)
  • Classic Fabry: Acroparesthesia (burning pain hands/feet), angiokeratomas, anhidrosis, GI symptoms
  • Later-Onset: Cardiac (LVH), renal (proteinuria/CKD), cerebrovascular (stroke age 30-50)

Ada Surface Ability: 9/10

Classic Fabry: Symptom triad (acroparesthesia + angiokeratomas + GI + family history X-linked) → order alpha-galactosidase A enzyme assay.

Later-Onset: Cardiac/renal symptoms + young age + family history → screening for Fabry in unexplained LVH, CKD, stroke <50.

Deduction (9/10 not 10/10): Later-onset harder to identify (cardiac/renal symptoms common). Requires specialist confirmation.

Company Motivation: 8/10

  • Massive underdiagnosis: 82% undiagnosed USA, 85% DACH
  • Revenue opportunity: $1.87B addressable USA (vs. $575M current; 3.2x upside)
  • Mature product stagnation: Flat growth (+0.1% FY 2025); patient finding only path
  • Competitive defense: Galafold oral eroding share; find NEW patients

Deduction (8/10 not 10/10): Not Sanofi's #1 priority (mature asset vs. Dupixent/ALTUVIIIO). Galafold competition for amenable mutations.

Pitch Hook: "Fabry disease patients wait 10-15 years for diagnosis—developing irreversible heart failure, kidney failure, and strokes while their neuropathic pain and skin lesions are dismissed as unrelated symptoms—and at $170,000 annual revenue per patient, Ada Patient Finder can identify the 40,800 undiagnosed US patients (82% underdiagnosis rate) through symptom assessment and family history algorithms, unlocking a $1.9 billion addressable market while Fabrazyme revenue stagnates."

Market Opportunity

Region Addressable Undiagnosed Net Revenue/Patient Ada Revenue Opportunity (5% capture)
USA 2,250 $100,000/year $1.13M/year
DACH 950 $76,000/year $365K/year
ROW 6,500 $65,000/year $2.11M/year

Clinical Profile

  • Diagnostic Delay: 6-12 months from first symptoms to MM diagnosis
  • Symptoms: Bone pain, fatigue/anemia, recurrent infections, renal dysfunction, hypercalcemia
  • Why Delayed: Elderly (median age 69) attribute symptoms to aging; nonspecific symptoms
  • Common Misdiagnoses: Osteoporosis/arthritis, anemia of chronic disease, recurrent UTIs/pneumonia

Ada Surface Ability: 6/10

Symptom triad (bone pain + fatigue + recurrent infections age 60+) → "Consider MM; order SPEP, CBC."

Challenges: Elderly population (median 69; lower smartphone penetration 60-70%). Diagnostic delay shorter than rare diseases (6-12 months vs. 5-10 years). Addressable population small (2,250 USA vs. 8-10K Pompe). Symptoms common in elderly; differentiation difficult.

Company Motivation: 7/10

  • Growing asset: +28.5% FY 2025; oncology franchise priority
  • Diagnostic delay exists: 6-12 months; patient finding shortens, captures before Darzalex
  • Front-line expansion: EU/Japan approved NDMM; US filing pending 2026
  • Subcutaneous formulation: IRAKLIA success (Jan 2025); SC launches 2026-2027

Deduction (7/10 not 10): Not top priority (€588M vs. Dupixent €15.7B). Addressable modest ($225M USA vs. $2.25B Nexviazyme). Elderly targeting challenge.

Pitch Hook: "Multiple myeloma patients—often in their late 60s and 70s—wait 6-12 months from first symptoms (bone pain, fatigue, anemia) to diagnosis, with thousands attributing symptoms to aging while primary care providers miss the disease, and at $100,000 net revenue per patient annually, Ada Patient Finder's symptom assessment can identify the classic triad and prompt SPEP testing, capturing 2,250 delayed US diagnoses worth $225 million annually."

Drugs with No Patient Finder Fit

ALTUVIIIO (Hemophilia A) - Fit Score: 3/10

Why No Fit: Severe hemophilia A diagnosed in infancy (bleeding episodes; no diagnostic delay). Mild/moderate hemophilia has diagnostic delay (7+ years females, 8+ months males), BUT not prophylaxis-eligible (ALTUVIIIO's $350K/year revenue is prophylaxis; mild/moderate use on-demand ~$20-50K/year). Addressable: <500 USA mild/moderate undiagnosed. Conclusion: Blockbuster via market share capture from Eloctate/factor VIIIs/HEMLIBRA, NOT patient finding.

Beyfortus (RSV Prevention) - Fit Score: 2/10

Why No Fit: Prevention product (no disease to diagnose; no diagnostic delay). Revenue per patient: $250-400 one-time/annual dose (vs. Dupixent $22K/year). Gap: Vaccination access gap (640K-1M infants annually), not undiagnosed disease. Better fit: Public health campaigns (CDC, AAP, pediatrician outreach), not individual patient finding.

Lantus/Toujeo (Diabetes) - Fit Score: 1/10

Why No Fit: LOE/biosimilar market (Lantus LOE 2015; generics eroding). Revenue per patient: $2-5K/year net (after biosimilar competition). Insulin users already diagnosed with diabetes (Ada irrelevant). Undiagnosed diabetes exists (~8-10M USA type 2), but Sanofi lacks GLP-1 asset; undiagnosed would start on metformin/GLP-1, not insulin.

Aubagio (Multiple Sclerosis) - Fit Score: 1/10

Why No Fit: LOE 2023; generic competition; sales declining -35.4% FY 2025. Revenue per patient: $5-10K/year post-generic. MS underdiagnosis exists (10-20%; 1-2 year delay), but newly diagnosed would start on newer DMTs (Ocrevus, Tysabri, Kesimpta), not generic Aubagio.

Recommended Partnership Structure

Immediate Actions (Tier 1 Drugs)

1. Nexviazyme (Pompe Disease)

2. Dupixent (Multi-Indication)

3. Fabrazyme (Fabry Disease)

Total Partnership Value (5% Capture Scenario)

Region Annual Ada Revenue (Tier 1 + Tier 2) Annual Sanofi Drug Revenue Unlocked
USA $162M/year $1.62B/year
DACH $22.5M/year $225M/year
ROW $33M/year $330M/year
GLOBAL TOTAL $217.5M/year $2.175B/year

Contract Structure